Compounds > diltiazem

Page last updated: 2024-08-23

diltiazem and sufentanil

diltiazem has been researched along with sufentanil in 8 studies

Research

Studies (8)

Timeframe	Studies, this research(%)	All Research%
pre-1990	1 (12.50)	18.7374
1990's	0 (0.00)	18.2507
2000's	4 (50.00)	29.6817
2010's	3 (37.50)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Cianchetta, G; Cruciani, G; Fravolini, A; Giesing, D; Singleton, RW; Vaz, RJ; Wildgoose, M; Zhang, M	1
Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL	1
Lombardo, F; Obach, RS; Waters, NJ	1
Chupka, J; El-Kattan, A; Feng, B; Miller, HR; Obach, RS; Troutman, MD; Varma, MV	1
Chang, G; El-Kattan, A; Miller, HR; Obach, RS; Rotter, C; Steyn, SJ; Troutman, MD; Varma, MV	1
Bellman, K; Knegtel, RM; Settimo, L	1
Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K	1
Kampine, JP; Schmeling, WT; Warltier, DC	1

Reviews

1 review(s) available for diltiazem and sufentanil

Article	Year
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans. Drug discovery today, 2016, Volume: 21, Issue:4 Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk	2016

Other Studies

7 other study(ies) available for diltiazem and sufentanil

Article	Year
A pharmacophore hypothesis for P-glycoprotein substrate recognition using GRIND-based 3D-QSAR. Journal of medicinal chemistry, 2005, Apr-21, Volume: 48, Issue:8 Topics: ATP Binding Cassette Transporter, Subfamily B, Member 1; Biological Transport; Caco-2 Cells; Fluoresceins; Fluorescent Dyes; Humans; Models, Molecular; Multivariate Analysis; Permeability; Quantitative Structure-Activity Relationship	2005
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling. Current drug discovery technologies, 2004, Volume: 1, Issue:4 Topics: Adverse Drug Reaction Reporting Systems; Artificial Intelligence; Computers; Databases, Factual; Drug Prescriptions; Drug-Related Side Effects and Adverse Reactions; Endpoint Determination; Models, Molecular; Quantitative Structure-Activity Relationship; Software; United States; United States Food and Drug Administration	2004
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds. Drug metabolism and disposition: the biological fate of chemicals, 2008, Volume: 36, Issue:7 Topics: Blood Proteins; Half-Life; Humans; Hydrogen Bonding; Infusions, Intravenous; Pharmacokinetics; Protein Binding	2008
Physicochemical determinants of human renal clearance. Journal of medicinal chemistry, 2009, Aug-13, Volume: 52, Issue:15 Topics: Humans; Hydrogen Bonding; Hydrogen-Ion Concentration; Hydrophobic and Hydrophilic Interactions; Kidney; Metabolic Clearance Rate; Molecular Weight	2009
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination. Journal of medicinal chemistry, 2010, Feb-11, Volume: 53, Issue:3 Topics: Administration, Oral; Biological Availability; Humans; Intestinal Absorption; Pharmaceutical Preparations	2010
Comparison of the accuracy of experimental and predicted pKa values of basic and acidic compounds. Pharmaceutical research, 2014, Volume: 31, Issue:4 Topics: Chemistry, Pharmaceutical; Forecasting; Hydrogen-Ion Concentration; Pharmaceutical Preparations; Random Allocation	2014
Negative chronotropic actions of sufentanil and vecuronium in chronically instrumented dogs pretreated with propranolol and/or diltiazem. Anesthesia and analgesia, 1989, Volume: 69, Issue:1 Topics: Analgesics; Animals; Diltiazem; Dogs; Drug Interactions; Electrocardiography; Fentanyl; Heart Rate; Hemodynamics; Naloxone; Propranolol; Sufentanil; Vecuronium Bromide	1989